What's new

Finalists of the BioFinland pitching competition have been selected

Here are the finalists of the BioFinland Pitching competition for students in Finnish universities and universities of applied sciences:

Aethra
Jakob German, Essi Viippola, Matteo Ferro

AlgaLab
Saana Soppela, Minne Jartti, Stina Gröhn

Obesity Curiosity
Suvi Laitinen

Novel Neuroregenerative Agents
Sven Sakson

► Register for audience

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian Oy, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announces a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.

The new facility will cover an area of 6,400 sqm (69,000 sqft), and house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products), such as adenoviral and AAV (adeno-associated viral) therapies. It will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture. The expanded facility will adhere to current good manufacturing practices (cGMP) and fulfilling both EU and US GMP requirements ensuring the delivery of safe, reliable, and compliant biopharmaceutical products.

Finnish Bioindustries FIB appoints Alexandra Peth as Managing Director

Finnish Bioindustries long-term director Carmela Kantor-Aaltonen is retiring in August 2023. M.Sc. Alexandra Peth has been appointed as her successor, in a  Managing Director role for Finnish Bioindustries starting on August 1st, 2023.

Alexandra currently works as Senior Advisor of innovation and finance at Chemical Industry Federation of Finland. She will continue working for Chemical Industry Federation of Finland beside her role as Managing Director of Finnish Bioindustries.

  1. Organon to acquire Forendo Pharma – acquisition adds pipeline of candidates targeting novel treatments in women’s health
  2. BioFinland Pitching Competition Final event video recording
  3. Biomarker Commercialization Tools now available (at biomarker.nu)
  4. AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
  5. Commercializing IVD-Applicable Biomarkers: Best Practices and Pitfalls Handbook is now available
  6. #TogetherAgainstCOVID19 – EuropaBio Interview with Finnish Bioindustries
  7. Quest Diagnostics Acquires Blueprint Genetics to Broaden Access to Actionable Insights for Genetic and Rare Diseases
  8. Blueprint Genetics expands in North America by building a new CLIA/CAP NGS facility in Seattle
  9. DelSiTech Ltd Receives Significant Funding for Developing Long-Acting Injectables for contraceptives and HIV antivirals development by the Bill & Melinda Gates Foundation
  10. Helsinki Biobank and Fimmic Introduce a Unique One Access Service for Biomedical Research
  11. Life Science Mentors – Mentoring Service for Finnish Life Science Actors
  12. Faron Pharmaceuticals Admission to AIM and first day of dealings £10 million fundraise to progress Phase III clinical trial
  13. Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen
  14. Fimmic closes investment round to digitalize cancer diagnostics
  15. Faron Pharmaceuticals Oy Intention to Float on AIM
  16. Innomedica to open new office in Switzerland
  17. FIT Biotech’s Initial Public Offering Completed Successfully
  18. BioFinland prize to Biovian Oy
  19. Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men
  20. Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102
  21. Promising new treatment for life threatening acute respiratory distress syndrome (ARDS)
  22. A Special Year for the Biotech Sector
  23. KU Leuven and FIT Biotech enter into a worldwide license and collaboration agreement for the development of novel immunotherapeutics
  24. Neste Jacobs and Roal Sign a Contract to Expand Enzyme Production Plant
  25. BioFinland 2013 prize to Glykos Finland Ltd
  26. Culminatum Innovation and Diaceutics Collaborate to Provide Expert Training to Leading Finnish Researchers on Commercializing Biomarkers for Personalized Medicine
  27. Innomedica and CMC Biologics into strategic agreement for Japan market
  28. The Future Generation of Bioscientists - Lost or Found?
  29. Culminatum works to develop an attractive innovation environment for biotechnology in the BSR
  30. New Horizons For the Bioindustry
  31. Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries
  32. An Insider’s View: Report on the Finnish Life Sciences Industry
  33. Faron and Maruishi Sign Traumakine-program License Agreement
  34. Rentschler to manufacture Faron product Traumakine®
  35. Change of management in Novamass Ltd
  36. Fulfilling the Promises
  37. Innomedica Expands in UK – Dr Jim Phillips Joins the Team
  38. Finland is a Forerunner in Biomass Refining
  39. Biobanks—Opportunities Becoming Reality
  40. The Perceived Value-added of Venture Capital Investors: Evidence from Finnish biotechnology industry
  41. Coaching small biotech companies into success: The value-adding function of VC
  42. Promoting innovation by tax incentives—A review of strategies and their importance to biotech growth
  43. European Biotech industry figures show signs of chronic under-funding
  44. ETLA 2004 Survey on the Finnish Biotechnology Industry--Background and Descriptive Statistics
  45. State of the Biotechnology Industry
  46. Intellectual Capital and Anticipated Future Sales in Small and Medium-sized Biotechnology Companies
  47. Ownership and Financial Structure of Biotechnology SMEs: Evidence from Finland
  48. Findings of the ETLA Survey on Finnish Biotechnology Firms

FINNISH BIOINDUSTRIES FIB
Eteläranta 10, FI-00131 Helsinki
+358 50 404 5166